Insights into the FDA 2018 New Drug Approvals

Alaa       Bedair; Fotouh    R.    Mansour
doi:10.2174/1570163816666191202104315
Abstract

Objective: The Center of Drug Evaluation and Research (CDER) in the food and drug administration (FDA) approves new drugs every year. This review discusses the novel drugs of the FDA in 2018, with emphasis on the breakthrough drugs, the milestones in the approved list, and drugs with the highest expected sales in 2024.
Methods: The following scientific search engines were surveyed for the clinical trials of the drugs approved by the FDA in 2018: Pubmed, Springer link, ScienceDirect, Scopus, Wiley online library, Taylor and Francis, and Google Scholar. The total forecast sales were compared based on information from the Cortellis database, EvaluatePharma, and Nature Biobusiness Briefs.
Results: The 2018 year was full of good news for the drug market in the USA, with 59 new drug approvals by the FDA, which is the highest number of approvals in the last twenty years. The oncology and the antimicrobial drugs represent almost 50% of the new list, which gives hope to cancer patients and subjects with infectious diseases. In the 2018 FDA list, a number of drugs are expected to exceed 1$ billion dollars of sales by 2024.
Conclusion: The new drugs approved by the FDA in 2018 have been reviewed. This year showed the highest number of new drug approvals in the last two decades. Among the 59 drugs approved in 2018, 14 drugs are considered breakthroughs, which revive hope for many poorly managed diseases. The list also contains 19 drugs that are first in class and 43 that were given priority reviews.
Keywords: Drug discovery, food and drug administration, 2018 new drug approval list, drug blockbusters, Drug Evaluation and Research (CDER), antimicrobial resistance
Graphical Abstract

[1] 
Bubko I, Gruber BM, Anuszewska EL. The role of the proteasome for therapy of incurable diseases. Postepy Hig Med Dosw  2010; 64: 314-25.
[PMID: 20679687] 
[2] 
Penesyan A, Gillings M, Paulsen IT, Penesyan A, Gillings M, Paulsen IT. Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities. Molecules  2015; 20(4): 5286-98.
[http://dx.doi.org/10.3390/molecules20045286] [PMID: 25812150] 
[3] 
Lam WY, Fresco P. medication adherence measures: an overview. BioMed Res Int  2015; 2015217047
[http://dx.doi.org/10.1155/2015/217047] [PMID: 26539470] 
[4] 
Sundström J, Arima H, Jackson R, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med  2015; 162(3): 184-91.
[http://dx.doi.org/10.7326/M14-0773] [PMID: 25531552] 
[5] 
Elfatatry HM, Mabrouk MM, Hammad SF, Mansour FR, Kamal AH, Alahmad S. Development and validation of chemometric-assisted spectrophotometric methods for simultaneous determination of phenylephrine hydrochloride and ketorolac tromethamine in binary combinations. J AOAC Int  2016; 99(5): 1247-51.
[http://dx.doi.org/10.5740/jaoacint.16-0106] [PMID: 27522949] 
[6] 
Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Weekly versus daily dipeptidyl peptidase 4 inhibitor therapy for type 2 diabetes: Systematic review and meta-analysis. Diabetes Care  2018; 41(4): e52-5.
[http://dx.doi.org/10.2337/dc17-2095] [PMID: 29449311] 
[7] 
Mabrouk MM, Hammad SF, Mansour FR, et al. Development and validation of a reversed phase HPLC method for simultaneous determination of antidiabetic drugs alogliptin benzoate and pioglitazone HCl. Pharm Sin  2016; 7: 32-40.
[8] 
Hindocha S. Risk factors, disease associations, and dupuytren diathesis. Hand Clin  2018; 34(3): 307-14.
[http://dx.doi.org/10.1016/j.hcl.2018.03.002] [PMID: 30012291] 
[9] 
Llorens F, Zarranz J-J, Fischer A, Zerr I, Ferrer I. Fatal familial insomnia: clinical aspects and molecular alterations. Curr Neurol Neurosci Rep  2017; 17(4): 30.
[http://dx.doi.org/10.1007/s11910-017-0743-0] [PMID: 28324299] 
[10] 
Lotstein D, Jonas D, Kaye B. Management of severe perinatal osteogenesis imperfecta: A perfect role for palliative care. Pediatrics  2018; 141: 384-4.
[11] 
Citrome L. Breakthrough drugs for the interface between psychiatry and neurology. Int J Clin Pract  2016; 70(4): 298-9.
[http://dx.doi.org/10.1111/ijcp.12805] [PMID: 27028671] 
[12] 
Novel Drug Approvals for. 2018.https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018
[13] 
Drugs to Watch Archives. 2018.https://clarivate.com/cortellis/tag/drugs-to-watch-2018/
[14] 
EvaluatePharma World Preview. Outlook to  2018; 2024https://info.evaluategroup.com/WP2018-CS.html
[15] 
Baedeker M, Ringel M, Schulze U. FDA approvals hit all time high but average value slips again. Nat Rev Drug Discov  2018; 2019
[PMID: 30710141] 
[16] 
Urquhart L. Regulatory watch: FDA new drug approvals in Q1 2018. Nat Rev Drug Discov  2018; 17(5): 309.
[http://dx.doi.org/10.1038/nrd.2018.61] [PMID: 29700500] 
[17] 
Urquhart L. Regulatory watch: FDA new drug approvals in Q3 2018. Nat Rev Drug Discov  2018; 17(11): 779.
[http://dx.doi.org/10.1038/nrd.2018.194] [PMID: 30374181] 
[18] 
Markham A. Bictegravir: First global approval. Drugs  2018; 78(5): 601-6.
[http://dx.doi.org/10.1007/s40265-018-0896-4] [PMID: 29564777] 
[19] 
Mann JE. Apalutamide (Erleada®). Oncol Times  2018; 40: 16.
[http://dx.doi.org/10.1097/01.COT.0000546191.62002.e4] 
[20] 
Hoy SM. Patisiran: First global approval. Drugs  2018; 78(15): 1625-31.
[http://dx.doi.org/10.1007/s40265-018-0983-6] [PMID: 30251172] 
[21] 
Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag  2019; 9(1): 5-23.
[http://dx.doi.org/10.2217/nmt-2018-0033] [PMID: 30480471] 
[22] 
Reddy DS. The utility of cannabidiol in the treatment of refractory Epilepsy. Clin Pharmacol Ther  2017; 101(2): 182-4.
[http://dx.doi.org/10.1002/cpt.441] [PMID: 27506704] 
[23] 
Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol  2017; 16(6): 425-34.
[http://dx.doi.org/10.1016/S1474-4422(17)30083-2] [PMID: 28460892] 
[24] 
Alder Announces Eptinezumab Significantly Reduces Migraine
    Risk Meets Primary and All Key Secondary Endpoints in Pivotal
    PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention. Alder
    BioPharmaceuticals  https://investor.alderbio.com/news-releases/news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-risk
[25] 
Syed YY. Lanadelumab: First global approval. Drugs  2018; 78(15): 1633-7.
[http://dx.doi.org/10.1007/s40265-018-0987-2] [PMID: 30267321] 
[26] 
Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol  2012; 24(4): 353-61.
[http://dx.doi.org/10.1097/MEG.0b013e3283517998] [PMID: 22410711] 
[27] 
EBSCOhost. 133761637. New and evolving therapies for hereditary https://web.b.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=10885412&AN=133761637&h=3P82EGKmfrmbWCJQmoWobxpIt5bFRo%2FiPio3dRtCr3ggSF9SW7gWn%2F7DLumex3EScxgBteznX9z9OIs0q2Y3FQ%3D%3D&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3Fdirect%3Dtrue%26profile%3Dehost%26scope%3Dsite%26authtype%3Dcrawler%26jrnl%3D10885412%26AN%3D133761637
[28] 
Carr B, Giudice L, Dmowski WP, et al. Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study. J Endometr Pelvic Pain Disord  2013; 5(3): 105-15.
[PMID: 30320043] 
[29] 
Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril  2017; 108(1): 152-60.
[http://dx.doi.org/10.1016/j.fertnstert.2017.05.006] [PMID: 28579415] 
[30] 
Muñoz-Hernando L, Muñoz-Gonzalez JL, Marqueta-Marques L, et al. Endometriosis: alternative methods of medical treatment. Int J Womens Health  2015; 7: 595-603.
[PMID: 26089705] 
[31] 
Miyazaki T, Choi IY, Rubas W, et al. NKTR-181: A novel Mu-opioid analgesic with inherently low abuse potential. J Pharmacol Exp Ther  2017; 363(1): 104-13.
[http://dx.doi.org/10.1124/jpet.117.243030] [PMID: 28778859] 
[32] 
Schehlein EM, Robin AL. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. Drugs  2019; 79(10): 1031-6.
[http://dx.doi.org/10.1007/s40265-019-01130-z] [PMID: 31134520] 
[33] 
Zielińska M, Wasilewski A, Fichna J. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Investig Drugs  2015; 24(8): 1093-9.
[http://dx.doi.org/10.1517/13543784.2015.1054480] [PMID: 26065434] 
[34] 
Scully M, Cataland SR, Peyvandi F, et al. HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med  2019; 380(4): 335-46.
[http://dx.doi.org/10.1056/NEJMoa1806311] [PMID: 30625070] 
[35] 
Kappos L, Bar-Or A, Cree BAC, et al. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet  2018; 391(10127): 1263-73.
[http://dx.doi.org/10.1016/S0140-6736(18)30475-6] [PMID: 29576505] 
[36] 
Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol  2014; 5(3): 65-77.
[http://dx.doi.org/10.1177/2040620714532123] [PMID: 24883179] 
[37] 
Wilkinson ST, Sanacora G. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today  2019; 24(2): 606-15.
[http://dx.doi.org/10.1016/j.drudis.2018.11.007] [PMID: 30447328] 
[38] 
Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med  2017; 376(16): 1551-60.
[http://dx.doi.org/10.1056/NEJMoa1607017] [PMID: 28423301] 
[39] 
Saffari A, Weiler M, Hoffmann GF, Ziegler A. Gene therapies for neuromuscular diseases. Nervenarzt  2019; 90(8): 809-16.
[http://dx.doi.org/10.1007/s00115-019-0761-z] [PMID: 31286145] 
[40] 
Jones SM, Sicherer SH, Burks AW, et al. Consortium of Food Allergy Research. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol  2017; 139(4): 1242-52.
[http://dx.doi.org/10.1016/j.jaci.2016.08.017] [PMID: 28091362] 
[41] 
Drug Innovation - Novel Drug Approvals for. 2018.
[42] 
Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv  2018; 2(17): 2176-85.
[http://dx.doi.org/10.1182/bloodadvances.2018020644] [PMID: 30171081] 
[43] 
Weitz IC, Kulagin A, Nakao S, et al. A phase 3 study of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors: Results of a subgroup analysis with patients stratified by baseline hemolysis level. Transfusion History Blood  2018; 132: 627-7.
[http://dx.doi.org/10.1182/blood-2018-99-110623] 
[44] 
McKeage K. Ravulizumab: first global approval. Drugs  2019; 79(3): 347-52.
[http://dx.doi.org/10.1007/s40265-019-01068-2] [PMID: 30767127] 
[45] 
Nalley C. FDA approves first treatment for rare blood disease. Oncol Times  2018; 2018: 9-10.
[http://dx.doi.org/10.1097/01.COT.0000530518.93339.20] 
[46] 
O’Brien J, Rizzieri T, Rizzieri DA. Tagraxofusp. Recombinant human fusion protein of diphtheria toxin and IL-3, Treatment of blastic plasmacytoid dendritic cell neoplasm. Drugs Future  2018; 43: 873.
[http://dx.doi.org/10.1358/dof.2018.043.12.2898664] 
[47] 
Ammulu MA, Rosaiah G, Managmauri UK. L-Asparaginase a biotherapeutic for acute lymphoblastic leukemia- A molecular perspective. Curr Trends Biotechnol Pharm  2017; 11: 424-43.
[48] 
Quigley EMM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther  2009; 29(3): 315-28.
[http://dx.doi.org/10.1111/j.1365-2036.2008.03884.x] [PMID: 19035970] 
[49] 
Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am  2015; 44(1): 97-111.
[http://dx.doi.org/10.1016/j.gtc.2014.11.008] [PMID: 25667026] 
[50] 
Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood  2017; 129(2): 257-60.
[http://dx.doi.org/10.1182/blood-2016-10-745133] [PMID: 27908881] 
[51] 
Strupp M, Teufel J, Zwergal A, Schniepp R, Khodakhah K, Feil K. Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract  2017; 7(1): 65-76.
[http://dx.doi.org/10.1212/CPJ.0000000000000321] [PMID: 28243504] 
[52] 
Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol  2017; 35: LBA2501-1.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.LBA2501] 
[53] 
Cortes J. A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood  2016; 128: 99.
[http://dx.doi.org/10.1182/blood.V128.22.99.99] 
[54] 
Ragon BK, Savona MR. The challenge of treating myelodysplastic syndromes/myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk  2017; 17S: S37-42.
[http://dx.doi.org/10.1016/j.clml.2017.02.012] [PMID: 28760301] 
[55] 
Locatelli F, Jordan MB, Allen CE, et al. Safety and efficacy of emapalumab in pediatric patients with primary hemophagocytic lymphohistiocytosis. Blood  2018; 132: LBA-6.
[http://dx.doi.org/10.1182/blood-2018-120810] 
[56] 
Umezawa H, Mizuno S, Yamazaki H, Nitta K. Inhibition of DNA-dependent RNA synthesis by rifamycins. J Antibiot (Tokyo)  1968; 21(3): 234-6.
[http://dx.doi.org/10.7164/antibiotics.21.234] [PMID: 4876998] 
[57] 
DeLaCruz L, Pendyala S, Barnes C, Moran E, Haumann B, Feldman G. Trial in progress: A 52-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial to evaluate the safety and tolerability of a nebulized long-acting muscarinic antagonist (Revefenacin) in study participants with COPD. Chest  2016; 150: 866A.
[http://dx.doi.org/10.1016/j.chest.2016.08.966] 
[58] 
Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther  2018; 48: 71-9.
[http://dx.doi.org/10.1016/j.pupt.2017.10.003] [PMID: 28987804] 
[59] 
Syed YY. Lorlatinib: First global approval. Drugs  2019; 79(1): 93-8.
[http://dx.doi.org/10.1007/s40265-018-1041-0] [PMID: 30604291] 
[60] 
Greengard EG, Greengard GE. Molecularly targeted therapy for neuroblastoma. Children (Basel)  2018; 5(10): 142.
[http://dx.doi.org/10.3390/children5100142] [PMID: 30326621] 
[61] 
Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med  2018; 379(10): 913-23.
[http://dx.doi.org/10.1056/NEJMoa1716197] [PMID: 30184455] 
[62] 
Hoy SM. Talazoparib: First global approval. Drugs  2018; 78(18): 1939-46.
[http://dx.doi.org/10.1007/s40265-018-1026-z] [PMID: 30506138] 
[63] 
Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer  2016; 115(10): 1157-73.
[http://dx.doi.org/10.1038/bjc.2016.311] [PMID: 27736844] 
[64] 
Benson MD, Dasgupta NR, Monia BP. inotersen(transthyretin-specific antisense oligonucleotide)for treatment of transthyretin amyloidosis. Neurodegener Dis Manag  2018; 2018: 37.
[PMID: 30561247] 
[65] 
Dasgupta N, Benson M. Long-term treatment with inotersen for amyloid transthyretin amyloidosis cardiomyopathy. J Card Fail  2018; 24: S59.
[http://dx.doi.org/10.1016/j.cardfail.2018.07.263] 
[66] 
Traynor K. New drugs and dosage forms. Am J Health Syst Pharm 2018.
[67] 
Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother  2014; 58(2): 1127-35.
[http://dx.doi.org/10.1128/AAC.01242-13] [PMID: 24295985] 
[68] 
Pfaller MA, Huband MD, Rhomberg PR, Flamm RK. Surveillance of omadacycline activity against clinical isolates from a global collection (north america, europe, latin america, asia-western pacific), 2010-2011. Antimicrob Agents Chemother  2017; 61(5): e00018-17.
[http://dx.doi.org/10.1128/AAC.00018-17] [PMID: 28223386] 
[69] 
Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). Diagn Microbiol Infect Dis  2018; 91(2): 179-83.
[http://dx.doi.org/10.1016/j.diagmicrobio.2018.01.019] [PMID: 29571839] 
[70] 
Zhanel G, Critchley I, Lin L-Y, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother  2018; 63(1): e01297-18.
[http://dx.doi.org/10.1128/AAC.01297-18] [PMID: 30397052] 
[71] 
Markham A, Duggan S. Cemiplimab: First global approval. Drugs  2018; 78(17): 1841-6.
[http://dx.doi.org/10.1007/s40265-018-1012-5] [PMID: 30456447] 
[72] 
Shirley M. Dacomitinib: First global approval. Drugs  2018; 78(18): 1947-53.
[http://dx.doi.org/10.1007/s40265-018-1028-x] [PMID: 30506139] 
[73] 
Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol  2013; 24(3): 761-9.
[http://dx.doi.org/10.1093/annonc/mds503] [PMID: 23108949] 
[74] 
Lamb YN. Galcanezumab: First global approval. Drugs  2018; 78(16): 1769-75.
[http://dx.doi.org/10.1007/s40265-018-1002-7] [PMID: 30378008] 
[75] 
Khan S, Olesen A, Ashina M. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia  2017; 0: 1-16.
[PMID: 29110503] 
[76] 
Blair HA. Duvelisib: First global approval. Drugs  2018; 78(17): 1847-53.
[http://dx.doi.org/10.1007/s40265-018-1013-4] [PMID: 30430368] 
[77] 
Hoy SM. Fremanezumab: First global approval. Drugs  2018; 78(17): 1829-34.
[http://dx.doi.org/10.1007/s40265-018-1004-5] [PMID: 30406901] 
[78] 
Dhillon S. Moxetumomab Pasudotox: First global approval. Drugs  2018; 78(16): 1763-7.
[http://dx.doi.org/10.1007/s40265-018-1000-9] [PMID: 30357593] 
[79] 
Deeks ED. Doravirine: First global approval. Drugs  2018; 78(15): 1643-50.
[http://dx.doi.org/10.1007/s40265-018-0993-4] [PMID: 30341683] 
[80] 
Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs  2016; 76(5): 567-88.
[http://dx.doi.org/10.1007/s40265-016-0545-8] [PMID: 26863149] 
[81] 
Mcneil R. Rare eyes diseases: Progress continues with authorised orphan medicines and breakthrough technologies. Eye News  2018; 25: 1-4.
[82] 
Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia  2011; 52(Suppl. 2): 76-8.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03008.x] [PMID: 21463286] 
[83] 
Trivisano M, Specchio N, Vigevano F. Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. Eur J Paediatr Neurol  2015; 19(2): 248-50.
[http://dx.doi.org/10.1016/j.ejpn.2014.11.008] [PMID: 25510386] 
[84] 
Markham A. Migalastat: First global approval. Drugs  2016; 76(11): 1147-52.
[http://dx.doi.org/10.1007/s40265-016-0607-y] [PMID: 27351440] 
[85] 
Voelker R. Vaginal ring contraceptive remains effective for 1 Year. JAMA  2018; 320(11): 1098.
[http://dx.doi.org/10.1001/jama.2018.13299] [PMID: 30422285] 
[86] 
Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs  2012; 72(9): 1293-8.
[http://dx.doi.org/10.2165/11631090-000000000-00000] [PMID: 22686619] 
[87] 
Kim ES. Lusutrombopag: First global approval. Drugs  2016; 76(1): 155-8.
[http://dx.doi.org/10.1007/s40265-015-0525-4] [PMID: 26666417] 
[88] 
Długosz-Danecka M, Zdziarska J, Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol  2019; 15(4): 327-39.
[http://dx.doi.org/10.1080/1744666X.2019.1587294] [PMID: 30799645] 
[89] 
Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr  2013; 37(2): 274-80.
[http://dx.doi.org/10.1177/0148607112450301] [PMID: 22683685] 
[90] 
Diamond IR, Sterescu A, Pencharz PB, Wales PW. The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease. Pediatr Surg Int  2008; 24(7): 773-8.
[http://dx.doi.org/10.1007/s00383-008-2174-0] [PMID: 18504595] 
[91] 
Frampton JE. Tafenoquine: First Global Approval. Drugs  2018; 78(14): 1517-23.
[http://dx.doi.org/10.1007/s40265-018-0979-2] [PMID: 30229442] 
[92] 
Dhillon S. Ivosidenib: First global approval. Drugs  2018; 78(14): 1509-16.
[http://dx.doi.org/10.1007/s40265-018-0978-3] [PMID: 30209701] 
[93] 
Hoy SM. Tecovirimat: First global approval. Drugs  2018; 78(13): 1377-82.
[http://dx.doi.org/10.1007/s40265-018-0967-6] [PMID: 30120738] 
[94] 
Shirley M. Encorafenib and binimetinib: First global approvals. Drugs  2018; 78(12): 1277-84.
[http://dx.doi.org/10.1007/s40265-018-0963-x] [PMID: 30117021] 
[95] 
van Geel RMJM, Tabernero J, Elez E, et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without Alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov  2017; 7(6): 610-9.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0795] [PMID: 28363909] 
[96] 
Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer  2016; 16: 172.
[http://dx.doi.org/10.1186/s12885-016-2199-z] [PMID: 26925841] 
[97] 
Karaiskos I, Souli M, Giamarellou H. Plazomicin: An investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs  2015; 24(11): 1501-11.
[http://dx.doi.org/10.1517/13543784.2015.1095180] [PMID: 26419762] 
[98] 
Mega WM, Doyle-Eisele M, Cass RT, et al. Plazomicin is effective in a non-human primate pneumonic plague model. Bioorg Med Chem  2016; 24(24): 6429-39.
[http://dx.doi.org/10.1016/j.bmc.2016.08.049] [PMID: 27614915] 
[99] 
Wolstenholme AJ, Maclean MJ, Coates R, McCoy CJ, Reaves BJ. How do the macrocyclic lactones kill filarial nematode larvae? Invert Neurosci  2016; 16(3): 7.
[http://dx.doi.org/10.1007/s10158-016-0190-7] [PMID: 27279086] 
[100] 
Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med  2016; 374(13): 1243-52.
[http://dx.doi.org/10.1056/NEJMoa1507247] [PMID: 27028914] 
[101] 
Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine  2015; 2(4): 351-5.
[http://dx.doi.org/10.1016/j.ebiom.2015.02.015] [PMID: 26137574] 
[102] 
Thomas J, Levy H, Amato S, et al. PRISM investigators. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab  2018; 124(1): 27-38.
[http://dx.doi.org/10.1016/j.ymgme.2018.03.006] [PMID: 29653686] 
[103] 
McCafferty EH, Lyseng-Williamson KA. Avatrombopag in the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure: a profile of its use in the USA. Drugs Ther Perspect  2018; 1-6.
[104] 
Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol  2018; 183(3): 479-90.
[http://dx.doi.org/10.1111/bjh.15573] [PMID: 30191972] 
[105] 
Levien TL, Baker DE. Sodium zirconium cyclosilicate. Hosp Pharm  2019; 54(1): 12-9.
[http://dx.doi.org/10.1177/0018578718817470] [PMID: 30718929] 
[106] 
Pergolizzi JV, Annabi H, Gharibo C, LeQuang JA. The role of lofexidine in management of opioid withdrawal. Pain Ther  2018; 1-12.
[PMID: 30565033] 
[107] 
Raedler LA. Akynzeo (Netupitant and Palonosetron), a dual-acting
    oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting. Am Health Drug Benefits 2015; 8(Spec Feature): 44-8.
[PMID: 26629265] 
[108] 
Collins M. Burosumab: At long last, an effective treatment for FGF23-associated hypophosphatemia. J Bone Miner Res  2018; 33(8): 1381-2.
[http://dx.doi.org/10.1002/jbmr.3544] [PMID: 29989668] 
[109] 
Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs  2009; 12(3): 174-85.
[PMID: 19333898] 
[110] 
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood  2010; 115(13): 2578-85.
[http://dx.doi.org/10.1182/blood-2009-08-236471] [PMID: 19965662] 
[111] 
Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol  2018; 179(3): 615-22.
[http://dx.doi.org/10.1111/bjd.16724] [PMID: 29742274] 
[112] 
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat  2018; 29(6): 569-78.
[http://dx.doi.org/10.1080/09546634.2017.1422591] [PMID: 29532693] 
[113] 
Voelker R. New option for drug-resistant HIV. JAMA  2018; 319(15): 1540.
[PMID: 29677286] 
[114] 
Grasemann H. CFTR modulator therapy for cystic fibrosis. N Engl J Med  2017; 377(21): 2085-8.
[http://dx.doi.org/10.1056/NEJMe1712335] [PMID: 29099349] 
[115] 
Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol  2013; 40(1): 56-68.
[http://dx.doi.org/10.1053/j.seminoncol.2012.11.006] [PMID: 23391113] 
[116] 
Hromadik LK, Sturges L. Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A treatment of hope for patients with gastroenteropancreatic neuroendocrine tumors. J Radiol Nurs 2019.
[http://dx.doi.org/10.1016/j.jradnu.2018.11.003] 
Rights & Permissions Print Cite
Article Metrics
27
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1570163816666191202104315	Print ISSN 1570-1638
Publisher Name Bentham Science Publisher	Online ISSN 1875-6220
Current Drug Discovery Technologies

Insights into the FDA 2018 New Drug Approvals

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract
